Abiomed
Recovering hearts. Saving lives.
|
|
| Traded as |
NASDAQ: ABMD S&P 400 Component |
|---|---|
| Industry | Medical Devices |
| Founded | 1981 |
| Headquarters | Danvers, MA United States and Aachen, Germany |
|
Key people
|
Michael R. Minogue, CEO, President & Chairman of the board Mr. Michael Tomsicek, CFO Dr. David Weber, COO Dr. Seth Bilazarian, CMO |
| Products |
Impella AbioCor iPulse IAB AB5000 BVS 5000 |
| Revenue |
 US$329.5 Million (FY 2016)
|
|
US$65.1 Million (FY 2016)
|
|
|
US$38.1 Million (FY 2016)
|
|
| Total assets |
US$423 Million (FY 2016)
|
| Total equity |
US$369 Million (FY 2016)
|
|
Number of employees
|
800 (2016) |
| Website | www.abiomed.com |
Abiomed (NASDAQ: ABMD) is a manufacturer of medical implant devices, including the AbioCor artificial heart and Impella. It is headquartered in Danvers, Massachusetts and has two additional offices, one in Aachen, Germany, and another in Japan. It has 800 employees worldwide. Michael R. Minogue joined Abiomed in 2004, and serves as CEO, Chairman and President.
For fiscal year 2016, Abiomed reported $329.5 million in revenue, $65.1 million in operating income, $38.1 million in net income, $423 million in total assets, and $369 million in equity.
Abiomed was founded in Danvers by David M. Lederman in 1981 as Applied Medical Corporation, and began working on the development of an artificial heart. Funded by federal research grants, Lederman partnered with The Texas Heart Institute to develop the AbioCor, implanting the first artificial heart into a Kentucky man in July 2001. Fourteen of the AbioCor devices were implanted, during clinical trials from 2001 to 2004, with the longest-living recipient surviving 512 days. The AbioCor won FDA approval in 2006 for patients who are near death and do not qualify for a heart transplant.
In 2004, Michael R. Minogue became president and CEO of Abiomed. In 2005, Abiomed purchased ventricular assist device company Impella CardioSystems AG of Aachen, Germany, maker of the Impella heart pump, developed by Thorsten Siess, who is now the Chief Technology Officer at Abiomed.
Since 2005, Impella heart devices have received a series of FDA approvals.
In 2007, the Impella 2.5 heart pump was among 35 healthcare products to receive a 2007 Medical Design Excellence Award.
Minogue helped found the Medical Technology Veterans Program (MVP), a career training and mentorship initiative designed to help veterans entering the civilian workforce transition into jobs in the medical device and life sciences industries. He currently serves as chairman of the program.
...
Wikipedia